FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996896645> ?p ?o ?g. }

• W1996896645 endingPage "S155" @default.
• W1996896645 startingPage "S152" @default.
• W1996896645 abstract "With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer has reached such a magnitude of beneficial effect as trastuzumab. This targeted agent (monoclonal antibody) is associated with a significant improvement in both disease-free (DFS) and overall survival (OS) in women with HER-2 positive breast cancer when given in combination with or in sequence to adjuvant chemotherapy. This has been confirmed in a recent Cochrane meta-analysis of randomized controlled trials (RCTs), including 6 adjuvant and 2 neoadjuvant studies (NSABP B-31, NCCTG N9831, BCIRG 006, HERA, FinHer, PACS-04, Buzdar and NOAH), with data collection until February 2010. Overall, mortality is reduced by one-third and the risk of relapse by 40%.Concerns regarding cardiac dysfunction are declining, with reports indicating its reversibility in most instances, however truly long term cardiac evaluation is still lacking.Hence, the benefit of trastuzumab could be challenged by cardiac toxicity, in lower-risk patients [T1a,b node-negative (N0) tumors] or those with increased cardiovascular risk (older women and patients with previous significant heart disease/suboptimal left ventricular ejection fraction [LVEF (<55%)], all of whom were largely excluded from the aforementioned adjuvant RCTs. These patient subgroups might warrant a specific approach, such as anti-HER2 treatment combined with just a taxane (avoiding anthracyclines) or with endocrine therapy. Reasonably large phase II trials aimed at exploring these more individualized regimens are underway in the US.The optimal duration of trastuzumab therapy remains unknown since the selection of the one year duration in the pivotal trials was arbitrary. The HERA trial showed that prolonging trastuzumab administration to two years does not confer additional advantage over one year. The PHARE trial compared 6 versus 12 months of trastuzumab and failed to show non-inferiority of the shorter treatment administration. At the present time, one year of adjuvant trastuzumab remains the standard-of-care until results from SOLD, Short-HER and PERSEPHONE consolidate or negate this finding.The route of trastuzumab administration has also been recently challenged. A subcutaneous formulation is being evaluated in several studies. The HannaH phase III trial compared the subcutaneous (SC) to the intravenous (IV) formulation of trastuzumab. The former was proven non-inferior to the latter, although the incidence of serious adverse events was slightly higher in the SC arm. The authors concluded that SC trastuzumab, administered at a fixed dose of 600 mg over 5 min, is a valid alternative option, with the potential for human and economic savings in clinical practice." @default.
• W1996896645 created "2016-06-24" @default.
• W1996896645 creator A5012100026 @default.
• W1996896645 creator A5065146236 @default.
• W1996896645 creator A5067552665 @default.
• W1996896645 creator A5081663693 @default.
• W1996896645 date "2013-08-01" @default.
• W1996896645 modified "2023-10-18" @default.
• W1996896645 title "Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies" @default.
• W1996896645 cites W2053396193 @default.
• W1996896645 cites W2060942118 @default.
• W1996896645 cites W2096884232 @default.
• W1996896645 cites W2097541112 @default.
• W1996896645 cites W2098775844 @default.
• W1996896645 cites W2107103026 @default.
• W1996896645 cites W2113450161 @default.
• W1996896645 cites W2130034035 @default.
• W1996896645 cites W2132893003 @default.
• W1996896645 cites W2140354367 @default.
• W1996896645 cites W2146384083 @default.
• W1996896645 cites W2149908785 @default.
• W1996896645 cites W2233806202 @default.
• W1996896645 doi "https://doi.org/10.1016/j.breast.2013.07.029" @default.
• W1996896645 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24074778" @default.
• W1996896645 hasPublicationYear "2013" @default.
• W1996896645 type Work @default.
• W1996896645 sameAs 1996896645 @default.
• W1996896645 citedByCount "82" @default.
• W1996896645 countsByYear W19968966452014 @default.
• W1996896645 countsByYear W19968966452015 @default.
• W1996896645 countsByYear W19968966452016 @default.
• W1996896645 countsByYear W19968966452017 @default.
• W1996896645 countsByYear W19968966452018 @default.
• W1996896645 countsByYear W19968966452019 @default.
• W1996896645 countsByYear W19968966452020 @default.
• W1996896645 countsByYear W19968966452021 @default.
• W1996896645 countsByYear W19968966452022 @default.
• W1996896645 countsByYear W19968966452023 @default.
• W1996896645 crossrefType "journal-article" @default.
• W1996896645 hasAuthorship W1996896645A5012100026 @default.
• W1996896645 hasAuthorship W1996896645A5065146236 @default.
• W1996896645 hasAuthorship W1996896645A5067552665 @default.
• W1996896645 hasAuthorship W1996896645A5081663693 @default.
• W1996896645 hasBestOaLocation W19968966451 @default.
• W1996896645 hasConcept C121608353 @default.
• W1996896645 hasConcept C126322002 @default.
• W1996896645 hasConcept C143998085 @default.
• W1996896645 hasConcept C2777863537 @default.
• W1996896645 hasConcept C2777982462 @default.
• W1996896645 hasConcept C2778198053 @default.
• W1996896645 hasConcept C2779786085 @default.
• W1996896645 hasConcept C530470458 @default.
• W1996896645 hasConcept C71924100 @default.
• W1996896645 hasConcept C78085059 @default.
• W1996896645 hasConceptScore W1996896645C121608353 @default.
• W1996896645 hasConceptScore W1996896645C126322002 @default.
• W1996896645 hasConceptScore W1996896645C143998085 @default.
• W1996896645 hasConceptScore W1996896645C2777863537 @default.
• W1996896645 hasConceptScore W1996896645C2777982462 @default.
• W1996896645 hasConceptScore W1996896645C2778198053 @default.
• W1996896645 hasConceptScore W1996896645C2779786085 @default.
• W1996896645 hasConceptScore W1996896645C530470458 @default.
• W1996896645 hasConceptScore W1996896645C71924100 @default.
• W1996896645 hasConceptScore W1996896645C78085059 @default.
• W1996896645 hasLocation W19968966451 @default.
• W1996896645 hasLocation W19968966452 @default.
• W1996896645 hasLocation W19968966453 @default.
• W1996896645 hasOpenAccess W1996896645 @default.
• W1996896645 hasPrimaryLocation W19968966451 @default.
• W1996896645 hasRelatedWork W1722328147 @default.
• W1996896645 hasRelatedWork W2029735288 @default.
• W1996896645 hasRelatedWork W2098775844 @default.
• W1996896645 hasRelatedWork W2287934179 @default.
• W1996896645 hasRelatedWork W2313919221 @default.
• W1996896645 hasRelatedWork W2934076975 @default.
• W1996896645 hasRelatedWork W3213317935 @default.
• W1996896645 hasRelatedWork W4254570048 @default.
• W1996896645 hasRelatedWork W2342209702 @default.
• W1996896645 hasRelatedWork W2498553990 @default.
• W1996896645 hasVolume "22" @default.
• W1996896645 isParatext "false" @default.
• W1996896645 isRetracted "false" @default.
• W1996896645 magId "1996896645" @default.
• W1996896645 workType "article" @default.